[177Lu]Lu-Comb-2

Radionuclide: Lu-177 t½ 9584.6 min
Modality: Therapy
Production route: —
Stage: Preclinical
Syntheses indexed: 1

Glioma and brain tumours Preclinical only, no clinical indication yet

What it is

Compound class: DOTA-conjugated chimeric peptide (DOTA-PEG6-d-PepH3-TPP)
Target / mechanism: Targets membrane-bound heat shock protein 70 (mHsp70), overexpressed in glioblastoma, via the TPP sequence PMID 42306550
Clinical application: Glioblastoma imaging and therapy PMID 42306550
Theranostic pair: —

Published syntheses

Module	Cassette	Purification	Yield %	RCP %	Precursor / supplier	Source
Manual synthesis	—	HPLC	—	≥95%	DOTA-PEG6-d-PepH3-TPP (Comb-2)	42306550 2026 Chem Sci each compound (1 µL, 1 mM in DMSO) was added to 10 µL of sodium acetate buffer

Need this precursor?We can point you to suppliers for [177Lu]Lu-Comb-2, or handle the enquiry for you.

Get in touch

Notes

Added at stage 22: promoted from 'Reported once' (single-article, no diagnostic pair at discovery) because a full-text synthesis with extracted data exists in parsed-therapy.xlsx -- PMID(s): 42306550. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Compound class inferred from precursor name (not stated outright) -- PMID 42306550: 'Comb-2 (DOTA-PEG6-d-PepH3-TPP)'. Stage set/updated at stage 39 from PMID 42306550: 'Biodistribution experiments with 67Ga-labeled compounds were performed in naive female CD1 mice'.